Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20466770 | 0.94 | GPR84 (0.31) | GPR84 | |
| SCHEMBL20466643 | 0.94 | GPR84 (0.31) | GPR84 | |
| SCHEMBL20466666 | 0.93 | GPR84 (0.32) | PDK2GPR84HPGD | |
| SCHEMBL20466772 | 0.93 | GPR84 (0.32) | PDK2GPR84HPGD | |
| SCHEMBL20755496 | 0.93 | GPR84 (0.34) | GPR84CYP1A1CYP1A2CYP1B1XDH | |
| SCHEMBL17790272 | 0.92 | GPR84 (0.32) | PDK2GPR84CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL20755093 | 0.91 | GPR84 (0.34) | PDK2GPR84CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL20466780 | 0.91 | GPR84 (0.30) | GPR84 | |
| SCHEMBL20466786 | 0.91 | GPR84 (0.30) | GPR84 | |
| SCHEMBL20466757 | 0.91 | GPR84 (0.31) | GPR84CYP1A1CYP1A2CYP1B1XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-08-29 | — | — | US | disclosed |
| US-20180226579-A1 | AMINE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180226579-A1 | AMINE-BASED COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | AOC2, AOC1, EML4 | PDK2 1515/4885GPR84 1216/4885CYP1A1 848/4885 |
| US-11744146-B2 | Amine-based compound and organic light-emitting device including the same | AOC2, AOC1, EML4 | PDK2 1515/4885GPR84 1216/4885CYP1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.